Tagged with P

Switzerland Ophthalmology is one of the hottest niches in pharma right now. Investment is flowing in, M&A is up, and a broad cast of actors – from Big Pharma to legacy generics players and biotechs – are looking to get in on a market set to top USD 93.7 billion by…

Switzerland Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation.   For instance, in Bellinzona, the capital of the Italian-speaking Ticino canton, the Institute of Oncology Research (IOR) is working with…

Switzerland As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. In May 2025, the United States imposed tariffs of up to 39 percent on Swiss goods, putting pressure on Switzerland’s most important industrial sector, which is responsible for ten percent of GDP and 41 percent…

Switzerland In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies.   While much of the global narrative around the European life sciences market centres on doom and gloom (access delays for innovative medicines,…

Switzerland With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a super-size effect on the local economy, contributing up to a…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

Switzerland Helsinn has recently entered one of the most consequential transformations in its history. As it prepares for a new transition at the helm of the company, Executive Chairman Riccardo Braglia and outgoing Group CEO Melanie Rolli reflect on a period marked by strategic separation, operational reinvention, and renewed therapeutic ambition.…

USA Once centred on building awareness, the Alliance for Regenerative Medicine has grown into the world’s foremost advocate for the cell and gene therapy sector, bringing together more than 400 members across biotech, pharma, academia, and patient organisations. In this conversation, CEO Timothy Hunt discusses how the field is moving from…

Global First published in the September/October 2025 edition of ISPOR’s Value & Outcomes Spotlight, David Thompson (Rubidoux Research), Christopher Blanchette (Clinical, Medical and Regulatory Affairs), and Stephanie Earnshaw (Access Strategy Consulting) explore how health economics and outcomes research (HEOR) careers are being reshaped by a fast-changing industry. The authors examine why…

Global First published in the November 2025 issue of DIA’s Global Forum, this article by Victoria Gamermanusa (RWD Insights) tackles one of rare disease research’s toughest dilemmas: how to run credible efficacy trials when patient numbers make traditional statistics unworkable. She charts how AI, Bayesian methods, transfer learning, and synthetic data…

UK First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee (MHRA) dives into one of the UK’s most urgent research challenges: how to make clinical trials genuinely inclusive. The authors…

Brazil Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s elevation to a top-tier global market, outlines ambitious growth trajectories in Alzheimer’s disease and lupus, and addresses the complexities of…